Penn Pharma, pharmaceutical manufacturer and developer, has announced a £14 million investment in its South Wales UK facility to strengthen its offering for global supply and further build on the company’s established high tech manufacturing capabilities.
The investment sees the 33 year old company expand its specialist high containment facilities with a 15,000 sq ft new development and commercial manufacturing unit for tablets and capsules meeting the highest international Quality Standards. The new facility will enable the team at Penn to further build upon its established expertise in the manufacture of specialist drugs for the worldwide market.
Penn Pharma has a wealth of experience in successfully providing an integrated range of services for the development, manufacture and distribution of medicinal products to the global pharmaceutical market. This new facility will see the team at Penn build on their success in the oncology and orphan drug sector and allow for more frequent and larger scale project delivery.
© Copyright Mark Allen Group | Registered in England No. 0677986
